REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has more than 25 years of experience in biotech companies advancing novel drug candidates across all stages of development and building teams to ensure quality and safety.
“Alan is an experienced drug developer of novel medicines for rare diseases. He is passionate about improving the health and quality of life for patients,” said Julie Anne Smith, Chief Executive Officer of Nuvig Therapeutics. “In addition, Alan’s natural acumen for hiring talent is critical as we build a powerhouse at Nuvig, and I’m delighted to welcome him to the team.”
Dr. Glicklich added, “What excites me about Nuvig is the unique therapeutic approach and the possibilities it has to improve and extend the lives of patients with chronic inflammatory autoimmune diseases. I look forward to working with the high-caliber team at Nuvig to advance our clinical programs to maximize the therapeutic impact of this incredible opportunity in medicine.”
Prior to Nuvig, Dr. Glicklich was the Chief Medical Officer at Chinook Therapeutics, where he focused on biologics and small molecules for rare, chronic kidney diseases. While at Chinook, he built teams responsible for clinical development, clinical operations, medical affairs, biometrics, and regulatory pharmacovigilance. In addition, he designed and operationalized a successful Phase 3 registrational study for atrasentan, a novel, selective endothelin A receptor antagonist (SERA). Before working at Chinook, Dr. Glicklich was the Chief Medical Officer at Bird Rock Bio, focusing on monoclonal antibody development for inflammatory and fibrotic diseases. Prior to Bird Rock Bio, he was the Vice President of Clinical Development at Arena Pharmaceuticals where he designed and oversaw operations for several Phase 2 programs, including ralinepag in pulmonary artery hypertension and the etrasimod program for ulcerative colitis. Earlier in his career Dr. Glicklich held positions at Bristol Myers Squibb, Sanofi-Aventis, and Regeneron. Dr. Glicklich received a B.A. in biology from the University of Chicago and an M.D. from the University of Wisconsin. He also holds an MBA from Emory University Goizueta Business School.
About Nuvig Therapeutics
Nuvig Therapeutics is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. For more info, visit www.nuvigtherapeutics.com.